MALVERN, PA, Jul 22, 2010 (MARKETWIRE via COMTEX) --
Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty
biopharmaceutical company, will release results for the second
quarter 2010 on Thursday, August 5, 2010 before the opening of the
financial markets. The Company will also conduct a conference call
that day at 10:00 a.m. ET to discuss results and highlights of the
second quarter 2010. The presentation slides to be used during the
call will be available on the "For Investors" section of the Auxilium
web site under the "Presentations" tab beginning at 7 a.m. ET on
Thursday, August 5, 2010. A web cast of the conference call and the
presentation slides will be available on the "For Investors" section
of the Auxilium web site under the "Events" tab beginning at 10:00
a.m. ET on Thursday, August 5, 2010. A question and answer session
will follow the presentations.
Mr. Armando Anido, Chief Executive Officer and President, will host
the conference call.
Conference call details:
Date: Thursday, August 5, 2010
Time: 10:00 a.m. ET
Dial-in (U.S.): 866-713-8562
Dial-in (International): 617-597-5310
Web cast: http://ir.auxilium.com/
Passcode: AUXILIUM
To access an audio replay of the call:
Access number (U.S.): 888-286-8010
Access number (International): 617-801-6888
Replay Passcode #: 90551685
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical
company with a focus on developing and marketing products to
predominantly specialist audiences, such as urologists,
endocrinologists, certain targeted primary care physicians, hand
surgeons, subsets of orthopedic, general, and plastic surgeons who
focus on the hand, and rheumatologists. Auxilium markets XIAFLEX(R)
(collagenase clostridium histolyticum) for the treatment of adult
Dupuytren's contracture patients with a palpable cord and markets
Testim(R) 1%, a topical testosterone gel, for the treatment of
hypogonadism. Auxilium has four projects in clinical development.
XIAFLEX is in phase IIb of development for the treatment of
Peyronie's disease and is in phase II of development for treatment of
Frozen Shoulder syndrome (Adhesive Capsulitis). Auxilium's
transmucosal film product candidate for the treatment of overactive
bladder (AA4010) and its fentanyl pain product using its transmucosal
delivery system are in phase I of development. The Company is
currently seeking a partner to further develop these product
candidates. Auxilium has rights to additional pain products and
products for hormone replacement and urologic disease using its
transmucosal film delivery system. Auxilium also has options to all
indications using XIAFLEX for non-topical formulations. For
additional information, visit http://www.auxilium.com.
Safe Harbor Statement
SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM
ACT OF 1995
This release contains "forward-looking-statements" within the meaning
of The Private Securities Litigation Reform Act of 1995, including
statements regarding the Company's intention to announce the second
quarter 2010 results; products in development for Peyronie's disease,
Frozen Shoulder syndrome, overactive bladder, pain, hormone
replacement and urologic disease; and all other statements containing
projections, statements of future performance or expectations, our
beliefs or statements of plans or objectives for future operations
(including statements of assumption underlying or relating to any of
the foregoing). Forward-looking statements can generally be
identified by words such as "believe," "appears," "may," "could,"
"will," "estimate," "continue," "anticipate," "intend," "should,"
"plan," "expect," and other words and terms of similar meaning in
connection with any discussion of projections, future performance or
expectations, beliefs, plans or objectives for future operations
(including statements of assumption underlying or relating to any of
the foregoing). Actual results may differ materially from those
reflected in these forward-looking statements due to various factors,
including further evaluation of clinical data, results of clinical
trials, decisions by regulatory authorities as to whether and when to
approve drug applications, and general financial, economic,
regulatory and political conditions affecting the biotechnology and
pharmaceutical industries and those discussed in Auxilium's Annual
Report on Form 10-K for the year ended December 31, 2009 and in
Auxilium's Quarterly Report on Form 10-Q for the period ended March
31, 2010 under the heading "Risk Factors," which are on file with the
Securities and Exchange Commission (the "SEC") and may be accessed
electronically by means of the SEC's home page on the Internet at
http://www.sec.gov or by means of Auxilium's home page on the
Internet at http://www.Auxilium.com under the heading "For Investors
-- SEC Filings." There may be additional risks that Auxilium does not
presently know or that Auxilium currently believes are immaterial
which could also cause actual results to differ from those contained
in the forward-looking statements. Given these risks and
uncertainties, any or all of these forward-looking statements may
prove to be incorrect. Therefore, you should not rely on any such
factors or forward-looking statements.
In addition, forward-looking statements provide Auxilium's
expectations, plans or forecasts of future events and views as of the
date of this release. Auxilium anticipates that subsequent events and
developments will cause Auxilium's assessments to change. However,
while Auxilium may elect to update these forward-looking statements
at some point in the future, Auxilium specifically disclaims any
obligation to do so. These forward-looking statements should not be
relied upon as representing Auxilium's assessments as of any date
subsequent to the date of this release.
For More Information, Contact:
James E. Fickenscher
CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
Email Contact
William Q. Sargent, Jr.
V.P., I.R.
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
Email Contact
SOURCE: Auxilium Pharmaceuticals, Inc.
http://www2.marketwire.com/mw/emailprcntct?id=48AC95A645A0A095
http://www2.marketwire.com/mw/emailprcntct?id=7D2BEDC82A6B536F
